EY
EYPT.US EyePoint, Inc
- Market cap
- USD 25.7M
- P/E
- -
- P/B
- 0.17x
- ROE
- -337.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EYPT.US undervalued?
Graham numberThe Graham number of EyePoint, Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EyePoint, Inc fundamental analysis
No fundamental analysis for EyePoint, Inc yet.
EyePoint, Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EyePoint, Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase…
Full company profileEyePoint, Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EyePoint, Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.62M | 7.54M | 5.86M | 20.4M | 34.4M | 36.9M | 41.4M | 46.0M | 43.3M | 31.4M | 2.61M |
| Gross Profit | 1.62M | 7.54M | -13.9M | 17.7M | 28.6M | 28.8M | 33.1M | 41.4M | 39.6M | 29.3M | 1.21M |
| Operating Income | -21.8M | -18.6M | -49.1M | -47.9M | -37.3M | -55.3M | -99.6M | -75.1M | -146M | -243M | -375M |
| EBITDA | -20.9M | -17.8M | -46.5M | -48.0M | -35.5M | -50.1M | -96.6M | -69.0M | -129M | -229M | -365M |
| Net Income | -21.5M | -18.5M | -53.2M | -56.8M | -45.4M | -58.4M | -102M | -70.8M | -131M | -232M | -367M |
| EPS | -6.81 | -5.23 | -12 | -5.44 | -3.54 | -2.03 | -2.74 | -1.82 | -2.32 | -3.17 | -4.11 |
| Balance Sheet | |||||||||||
| Total Assets | 18.7M | 18.7M | 71.7M | 73.0M | 91.7M | 263M | 180M | 355M | 418M | 364M | 166M |
| Total Liabilities | 5.34M | 5.34M | 60.0M | 64.6M | 73.2M | 79.0M | 84.0M | 88.9M | 82.0M | 57.9M | 57.6M |
| Shareholders' Equity | 13.3M | 13.3M | 11.7M | 8.33M | 18.5M | 184M | 96.4M | 266M | 337M | 306M | 109M |
| Cash & Short-term Investments | 16.9M | 16.9M | 38.8M | 22.2M | 44.9M | 212M | 145M | 331M | 371M | 306M | 118M |
| Total Debt | - | 17.3M | 17.7M | 50.6M | 46.4M | 39.2M | 46.3M | 4.91M | 21.9M | 22.8M | 19.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.3M | -20.5M | -21.9M | -56.7M | -14.4M | -50.1M | -65.0M | 1.88M | -126M | -240M | -306M |
| Capital Expenditure | 113K | 147K | 108K | 213K | 362K | 156K | 2.15M | 3.48M | 4.05M | 3.28M | 4.54M |
| Free Cash Flow | -16.4M | -20.6M | -22.0M | -56.9M | -14.8M | -50.3M | -67.2M | -1.61M | -130M | -243M | -311M |
| Ratios | |||||||||||
| ROE | -161.6% | -138.6% | -455.0% | -681.8% | -244.8% | -31.7% | -106.1% | -26.6% | -38.9% | -75.8% | -337.8% |
| ROA | -115.4% | -99.0% | -74.2% | -77.8% | -49.5% | -22.2% | -56.7% | -19.9% | -31.3% | -63.7% | -220.6% |
| Net Profit Margin | -1,330.1% | -245.2% | -908.0% | -278.9% | -131.8% | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% | -14,033.4% |
| Debt to Equity | - | 1.30x | 1.51x | 6.07x | 2.50x | 0.21x | 0.48x | 0.02x | 0.06x | 0.07x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
EyePoint, Inc dividends
EyePoint, Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Dec 9, 2020.
Who owns EyePoint, Inc
- Insiders 3.53%
- Institutions 96.48%
- Public & others 0.00%
- Shares outstanding 83.8M
- Free float 62.8M
Top funds holding EYPT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Federated Hermes Kaufmann R | 2.77M | 3.21% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.72M | 3.15% | 0.00% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.64M | 3.07% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 2.08M | 2.41% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann Small Cap A | 1.98M | 2.30% | 0.00% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 1.25M | 1.44% | 0.00% | Jun 2026 |
| Federated Hermes MDT Small Cap Core IS | 1.19M | 1.39% | +198.72% | Sep 2026 |
| Franklin Biotechnology Discovery A | 1.12M | 1.30% | 0.00% | Sep 2026 |
| Franklin Small Cap Growth Adv | 1.08M | 1.26% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 1.01M | 1.17% | +2.88% | Oct 2026 |
| abrdn Life Sciences Investors | 1.01M | 1.17% | +426.64% | Sep 2026 |
| HBM Healthcare Investments AG Ord | 1.00M | 1.16% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 890K | 1.03% | +5.14% | Aug 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 731K | 0.85% | +8.09% | Jun 2026 |
| Candriam Eqs L Biotech C USD Cap | 674K | 0.78% | 0.00% | Apr 2026 |
| iShares Russell 2000 Growth ETF | 614K | 0.71% | -0.38% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 477K | 0.55% | +743.43% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 464K | 0.54% | +0.24% | Oct 2026 |
| Vanguard Russell 2000 ETF | 448K | 0.52% | +0.91% | Sep 2026 |
| Fidelity Extended Market Index | 422K | 0.49% | +3.65% | Sep 2026 |
Top institutions holding EYPT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 8.30M | 9.62% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.46M | 8.66% | +3.98% | Jun 2026 |
| Cormorant Asset Management, LLC | 7.00M | 8.12% | -15.31% | Jun 2026 |
| Federated Hermes Inc | 5.68M | 6.59% | +0.20% | Jun 2026 |
| Adage Capital Partners Gp LLC | 4.83M | 5.60% | +46.30% | Jun 2026 |
| Franklin Templeton Inc | 4.81M | 5.58% | -4.78% | Jun 2026 |
| COMMODORE CAPITAL LP | 4.60M | 5.34% | +62.83% | Jun 2026 |
| Jupiter Topco LLC | 3.77M | 4.37% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.63M | 4.21% | +1.99% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 2.89M | 3.35% | -8.02% | Jun 2026 |
| State Street Corp | 2.36M | 2.73% | +12.41% | Jun 2026 |
| Geode Capital Management, LLC | 2.06M | 2.39% | +3.97% | Jun 2026 |
| Aberdeen Group PLC | 2.01M | 2.33% | +15.56% | Jun 2026 |
| Citadel Advisors Llc | 1.98M | 2.29% | +3.76% | Jun 2026 |
| Balyasny Asset Management LLC | 1.81M | 2.10% | +25.97% | Jun 2026 |
| Parkman Healthcare Partners LLC | 1.29M | 1.49% | -4.92% | Jun 2026 |
| Eventide Asset Management, LLC | 1.25M | 1.44% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 1.18M | 1.37% | +174.48% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.11M | 1.29% | +31.90% | Sep 2026 |
| Essex Woodlands Health Ventures | 1.08M | 1.26% | 0.00% | Jun 2026 |
EyePoint, Inc company profile
- Company name
- EyePoint, Inc
- Ticker
- EYPT.US
- Exchange
- USA Stocks
- Listed since
- Jan 27, 2005
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 214
- Fiscal year end
- December
- Address
- 480 Pleasant Street, Watertown, MA, United States, 02472
- Phone
- 617 926 5000
- Website
- eyepoint.bio
About EyePoint, Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
EyePoint, Inc management
10- Dr. Jay S. Duker M.D.President, CEO & Director · born 1959
- Mr. George O. Elston CPAExecutive VP & CFO · born 1965
- Dr. Ramiro Ribeiro M.D., Ph.D.Chief Medical Officer · born 1983
- Dr. Marcia Sellos-Moura Ph.D.Chief Scientific Officer
- Mr. Ron I. Honig Esq.Chief Legal Officer & Company Secretary
- Ms. Jennifer LeonardChief People Officer & Senior VP of IT
- Mr. David Scott Jones M.A.Senior Vice President · born 1968
- Ms. Isabelle LefebvreChief Regulatory Officer
- Mr. Michael J. MaciocioChief Manufacturing Officer
- Mr. Michael CampbellChief Commercial Officer